

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.

## Nanologica AB (publ) Announces the Outcome of the Exercise of Warrants of Series T05

**On May 21, 2025, the exercise period for Nanologica AB (publ) ("Nanologica" or the "Company") warrants of series T05 ended. A total of 12,586 warrants of series T05 have been exercised, corresponding to approximately 0.1 percent of the total number of warrants, meaning that the Company will receive approximately SEK 38 thousand before deduction of issue costs.**

In 2024, Nanologica issued a total of 11,044,654 warrants of series T05 within the framework of a rights issue of units. During the period May 7, 2025 up to and including May 21, 2025, holders of warrants of series T05 have had the right to subscribe for shares by virtue of warrants. One (1) warrant of series T05 entitled the holder to subscribe for one (1) new share in Nanologica at a subscription price set at SEK 3. A total of 12,586 warrants of series T05 have been exercised, corresponding to a subscription of SEK 37,758. The utilisation entails a dilution of approximately 0.014 per cent. The conversion of interim shares into shares is expected to take place within approximately two weeks.

After registration with the Swedish Companies Registration Office, the number of shares in the Company will have increased by 12,586 shares and amount to a total of 88,369,820 shares, and the share capital will have increased by SEK 641.886 and thus amount to SEK 4,506,860.82.

### **For further information, please contact**

Johanna Johansson  
Director IR, Communications and Marketing  
johanna.johansson@nanologica.com  
+46 72 211 21 90

### **About Nanologica AB (publ)**

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit [www.nanologica.com](http://www.nanologica.com).

**Attachments**

[Nanologica AB \(publ\) Announces the Outcome of the Exercise of Warrants of Series T05](#)